news
Teva completes acquisition of Labrys
...opens door to a strong and novel migraine prevention and…
21 July 2014 | By Teva
...opens door to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.
List view / Grid view
Michael Hayden
news
Teva reports positive results from pivotal Phase III study to evaluate hydrocodone bitartrate extended-release tablets (CEP-33237) for moderate to severe chronic low back pain
Data provides promise for a twice-daily, acetaminophen-free hydrocodone designed with…
30 April 2014 | By Teva
Data provides promise for a twice-daily, acetaminophen-free hydrocodone designed with potential abuse-deterrent properties...
news
Teva and OncoGenex announce top-line survival results of Phase III SYNERGY trial evaluating custirsen in combination with first-line docetaxel and prednisone for metastatic castrate-resistant prostate cancer
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced results…
28 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced results from the Phase III SYNERGY trial...
news
New data presented at 29th ECTRIMS Congress reinforce the clinical profile of investigational laquinimod on disease progression and inflammation in relapsing-remitting multiple sclerosis
Pooled data analysis of Phase III ALLEGRO and BRAVO studies…
4 October 2013 | By Teva Pharmaceutical Industries Ltd
Pooled data analysis of Phase III ALLEGRO and BRAVO studies add to our understanding of investigational laquinimod for relapsing-remitting Multiple Sclerosis...
news
Teva to present further results of twenty-year open-label extension study of glatiramer acetate 20 mg daily for relapsing-remitting Multiple Sclerosis
“To our knowledge, glatiramer acetate is the only treatment for…
3 October 2013 | By Teva Pharmaceutical Industries Ltd
“To our knowledge, glatiramer acetate is the only treatment for multiple sclerosis that has been prospectively studied for nearly two decades..."
news
Newly published phase III exploratory analysis suggests investigational oral laquinimod for multiple sclerosis may reduce brain damage caused by neurodegeneration
"This Phase III sub-study was pre-planned to explore the ability…
1 October 2013 | By Teva Pharmaceutical Industries Ltd
"This Phase III sub-study was pre-planned to explore the ability of laquinimod to act on mechanisms leading to irreversible brain tissue damage..."
news
Teva reports top-line results from final Phase III study of armodafinil (NUVIGIL®) in patients with major depression associated with bipolar I disorder
TEVA announced top-line results of its final Phase III clinical…
30 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced top-line results of its final Phase III clinical study for armodafinil (NUVIGIL®)...
news
Teva receives European Marketing Authorization for Lonquex® (XM22 lipegfilgrastim)
TEVA announced that the European Commission has granted marketing authorization…
8 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced that the European Commission has granted marketing authorization for Lonquex® (lipegfilgrastim)...
news
Teva’s Lonquex® (XM22 lipegfilgrastim) recommended for approval in the EU
Teva’s Lonquex® (XM22 lipegfilgrastim) recommended for approval in the EU…
3 June 2013 | By Teva Pharmaceutical Industries Ltd
Teva’s Lonquex® (XM22 lipegfilgrastim) recommended for approval in the EU for the reduction of CIN...
news
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
"We are pleased that the FDA has accepted for review…
30 May 2013 | By Teva Pharmaceutical Industries Ltd.
"We are pleased that the FDA has accepted for review our sNDA..."
news
Teva and Xenon announce FDA orphan drug designation for pain drug XEN402
"We are very pleased to receive orphan drug designation for…
23 April 2013 | By TEVA
"We are very pleased to receive orphan drug designation for XEN402..."
news
Teva Pharmaceutical’s new investigational treatment for MS
TEVA and Active Biotech announced top-line results from the open-label…
21 March 2013 | By PARADIGM COMMUNICATIONS
TEVA and Active Biotech announced top-line results from the open-label extension of the Phase III ALLEGRO study...
news
New data show Azilect® provided clinical benefit in patients with early Parkinson’s
Results add to evidence for Azilect as an effective and…
20 March 2013 | By H. Lundbeck A/S
Results add to evidence for Azilect as an effective and well-tolerated treatment option at different stages of the progression of PD...
news
New data presented at the 28th ECTRIMS Congress showcase Teva’s ongoing commitment to Multiple Sclerosis research
Key data from the Company’s MS franchise...
8 October 2012 | By Teva Pharmaceutical Industries Ltd
Key data from the Company’s MS franchise...
news
Teva to initiate Third Phase III Trial of oral laquinimod for the treatment of relapsing remitting multiple sclerosis
The clinical trial protocol has been granted a Special Protocol…
8 August 2012 | By Teva Pharmaceutical Industries Ltd
The clinical trial protocol has been granted a Special Protocol Assessment agreement...
